ArticleFrontiers in cell and developmental biology2026
Betaine restores OPA1-mediated mitochondrial fusion in alveolar epithelial type 2 cells and ameliorates hyperoxic lung injury in newborn mice.
Article in Frontiers in cell and developmental biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Bronchopulmonary dysplasia (BPD) is a common chronic respiratory disease in preterm infants, characterized by impaired lung development. Mitochondrial dysfunction of alveolar type II epithelial (AT2) cells plays a critical role in the pathogenesis of BPD. Betaine is an endogenous methyl donor with anti-inflammatory and antioxidant properties. Our previous study demonstrated that plasma betaine levels were significantly decreased in preterm infants with BPD. The aim of this study was to investigate the effect of betaine on mitochondrial dysfunction of AT2 cells in BPD. Methods: Hyperoxia-induced BPD mouse models and hyperoxia-exposed MLE-12 cells were used. Proteomic analysis was performed on lung tissues from BPD and control mice. Mitochondrial structure and function were assessed by transmission electron microscopy, immunofluorescence, Western blotting, flow cytometry, and related assays. The OPA1 inhibitor MYLS22 was used to evaluate the role of OPA1 in the protective effect of betaine. Results: Hyperoxia exposure induced mitochondrial structural damage in AT2 cells and impaired lung development in BPD mice. Proteomic analysis revealed that differentially expressed proteins were significantly enriched in mitochondrial dysfunction pathways in the lungs of BPD mice. Family with sequence similarity 162 member A (FAM162A), a mitochondria-associated protein involved in mitochondrial homeostasis, was prominently downregulated. Betaine significantly increased the expression of FAM162A and optic atrophy 1 (OPA1), suppressed the activating transcription factor 4 (ATF4) and C/EBP homologous protein (CHOP) mediated integrated stress response, and alleviated cell apoptosis in AT2 cells in BPD mice. In vitro, betaine increased the expression of FAM162A and OPA1, improved mitochondrial dysfunction and decreased cell apoptosis, and the effect was abolished by the OPA1 inhibitor MYLS22 in MLE-12 cells exposed to hyperoxia. Discussion: Our findings revealed that betaine ameliorated OPA1-mediated mitochondrial fusion in AT2 cells and alleviated hyperoxic lung injury in newborn mice, providing new insight for the prevention and treatment of BPD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.